MARKET

BHVN

BHVN

Biohaven Pharma
NYSE

Real-time Quotes | Nasdaq Last Sale

82.72
-3.66
-4.24%
Opening 14:00 03/02 EST
OPEN
86.23
PREV CLOSE
86.38
HIGH
86.34
LOW
82.34
VOLUME
208.09K
TURNOVER
--
52 WEEK HIGH
100.77
52 WEEK LOW
26.56
MARKET CAP
4.96B
P/E (TTM)
-6.7423
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
Zacks.com · 4h ago
--Analyst Actions: Mizuho Adjusts Price Target on Biohaven Pharmaceutical to $103 From $93, Maintains Buy Rating
MT Newswires · 7h ago
Rett Syndrome Therapeutics Industry 2021 Latest Update with Technological Advancement, Emerging Trends, Business Opportunity, Sales, Revenue, Gross Margin and Forecast to 2027
The Express Wire · 13h ago
10-K: BIOHAVEN PHARMACEUTICAL HOLDING CO LTD.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 20h ago
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board...
GlobeNewswire · 22h ago
DJ Biohaven Pharmaceutical Holding Company Ltd. CEO Vlad Coric on Q4 2020 Results -- Earnings Call Transcript >BHVN
Dow Jones · 22h ago
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
--Analyst Actions: Wedbush Lowers Price Target for Biohaven Pharmaceutical to $97 From $100, Maintains Outperform Rating
MT Newswires · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BHVN. Analyze the recent business situations of Biohaven Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BHVN stock price target is 97.45 with a high estimate of 125.00 and a low estimate of 67.00.
EPS
Institutional Holdings
Institutions: 358
Institutional Holdings: 65.17M
% Owned: 108.73%
Shares Outstanding: 59.94M
TypeInstitutionsShares
Increased
75
3.52M
New
74
-967.08K
Decreased
88
5.94M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.64%
Pharmaceuticals & Medical Research
-0.43%
Key Executives
Chairman/Director
Thomas Lynch
Chief Executive Officer/Director
Vlad Coric
Chief Financial Officer/Treasurer
James Engelhart
Senior Vice President
Kimberly Gentile
Chief Scientific Officer
Charles Conway
Other
Robert Berman
Other
William Jones
Other
Elyse Stock
Other
John Tilton
Director
Gregory Bailey
Director
John Childs
Director
Michael Heffernan
Director
Robert Hugin
Independent Director
Julia Gregory
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About BHVN
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.

Webull offers kinds of Biohaven Pharmaceutical Holding Co Ltd stock information, including NYSE:BHVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BHVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BHVN stock methods without spending real money on the virtual paper trading platform.